Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
BIDU-SW
09888
5
JD HEALTH
06618
| (Q9)Sep 30, 2025 | (Q6)Jun 30, 2025 | (Q1)Mar 31, 2025 | (FY)Dec 31, 2024 | (Q9)Sep 30, 2024 | (Q6)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q9)Sep 30, 2023 | (Q6)Jun 30, 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Turnover | 1.31%129.83B | 1.56%80.76B | -0.11%40.02B | 18.14%166.7B | 21.50%128.15B | 33.39%79.52B | 59.83%40.07B | 166.74%141.1B | 150.61%105.48B | 148.88%59.61B |
| Operating income | 1.31%129.83B | 1.56%80.76B | -0.11%40.02B | 18.14%166.7B | 21.50%128.15B | 33.39%79.52B | 59.83%40.07B | 166.74%141.1B | 150.61%105.48B | 148.88%59.61B |
| Operating expenses | -0.76%-120.66B | -2.80%-39.81B | -22.99%-119.75B | -47.15%-38.73B | -58.54%-97.36B | |||||
| Gross profit | 9.12%9.17B | -84.29%210.05M | 3.52%8.4B | 206.81%1.34B | 142.01%8.12B | |||||
| Selling expenses | -5.29%-5.26B | -5.91%-2.41B | -0.02%-1.74B | -37.16%-4.7B | -24.92%-4.99B | -47.56%-2.28B | -55.41%-1.74B | -108.76%-3.42B | -47.31%-4B | -69.74%-1.54B |
| Administrative expenses | -1.34%-3.97B | -2.22%-797.63M | -2.99%-1.33B | -11.22%-1.87B | -5.15%-3.92B | -10.50%-780.31M | -16.15%-1.29B | -35.71%-1.68B | -15.41%-3.73B | -39.03%-706.17M |
| Research and development expenses | -6.49%-312.48M | ---- | 0.07%-85.25M | ---- | -37.23%-293.45M | ---- | -22.43%-85.31M | ---- | -69.45%-213.84M | ---- |
| Profit from asset sales | -97.56%23.38M | ---- | 431.15%8.91M | ---- | 38.94%958.22M | ---- | -110.61%-2.69M | ---- | 21,814.86%689.66M | ---- |
| Employee expense | ---- | -5.28%-17.85B | ---- | -16.96%-34.27B | ---- | -24.71%-16.95B | ---- | -15.64%-29.3B | ---- | -18.79%-13.59B |
| Depreciation and amortization | ---- | -5.79%-14.84B | ---- | -7.35%-29.1B | ---- | -10.39%-14.03B | ---- | -27.68%-27.11B | ---- | -21.48%-12.7B |
| Revaluation surplus | 1,495.45%1.4M | ---- | -94.12%2K | ---- | 112.38%88K | ---- | 112.55%34K | ---- | -13.94%-711K | ---- |
| -Changes in the fair value of other assets | 1,495.45%1.4M | ---- | -94.12%2K | ---- | 112.38%88K | ---- | 112.55%34K | ---- | -13.94%-711K | ---- |
| Impairment and provision | -1,005.43%-95.13M | -508.63%-87.24M | 57.29%-4.27M | 36.82%-133.73M | 93.05%-8.61M | 86.04%-14.33M | -126.10%-10M | -406.39%-211.67M | -56,672.02%-123.76M | -745.47%-102.67M |
| -Other impairment is provision | -1,005.43%-95.13M | -508.63%-87.24M | 57.29%-4.27M | 36.82%-133.73M | 93.05%-8.61M | 86.04%-14.33M | -126.10%-10M | -406.39%-211.67M | -56,672.02%-123.76M | -745.47%-102.67M |
| Special items of operating profit | 6.46%5.75B | 0.17%-46.47B | 16.46%1.88B | -23.44%-94.41B | -0.94%5.4B | -46.11%-46.55B | 18.20%1.61B | -96.88%-76.48B | 260.58%5.45B | -80.80%-31.86B |
| Operating profit | -5.49%5B | -56.79%-1.7B | -379.96%-1.16B | -23.23%2.22B | -10.91%5.29B | -20.46%-1.08B | 89.18%-241.86M | 108.15%2.89B | 124.74%5.93B | 94.71%-898.2M |
| Financing income | ---- | 16.36%285.79M | ---- | -13.83%521.36M | ---- | -15.70%245.62M | ---- | 164.52%605M | ---- | 215.49%291.38M |
| Financing cost | 15.37%-3.77B | 11.47%-2.89B | 20.65%-1.35B | 7.84%-6.4B | 29.97%-4.46B | 7.82%-3.27B | -60.95%-1.7B | -7.27%-6.94B | 32.05%-6.36B | -12.76%-3.54B |
| Share of profits of associates | ---- | 12.48%1.22B | ---- | 2.20%2.61B | ---- | -14.28%1.08B | ---- | 635.05%2.55B | ---- | 221.53%1.27B |
| Share of profit from joint venture company | ---- | 28.29%117.21M | ---- | -25.20%209.12M | ---- | 2.86%91.36M | ---- | -25.82%279.57M | ---- | -60.85%88.82M |
| Special items of earning before tax | ---- | 148.92%176.31M | ---- | 26.63%-759.52M | ---- | 76.97%-360.42M | ---- | 74.68%-1.04B | ---- | 30.11%-1.57B |
| Adjustment items of earning before tax | -47.46%131.06M | ---- | 195.04%60.5M | ---- | -81.81%249.45M | ---- | 63.87%20.51M | ---- | 8,257.19%1.37B | ---- |
| Earning before tax | 25.60%1.36B | 15.16%-2.79B | -27.36%-2.45B | 3.09%-1.6B | 14.67%1.08B | 24.63%-3.29B | 41.32%-1.93B | 96.40%-1.65B | 102.82%941.12M | 81.11%-4.36B |
| Tax | 100.55%1.71M | 130.81%77.8M | -8.45%-82.14M | -1,056.13%-846.47M | -226.11%-309.88M | -179.86%-252.54M | -962.19%-75.74M | -87.41%88.53M | -74.14%245.72M | -63.30%316.22M |
| After-tax profit from continuing operations | 76.41%1.36B | 23.41%-2.71B | -26.64%-2.54B | -56.63%-2.45B | -35.18%769.27M | 12.50%-3.54B | 38.85%-2B | 96.54%-1.56B | 103.66%1.19B | 81.80%-4.04B |
| Earning after tax | 76.41%1.36B | 23.41%-2.71B | -26.64%-2.54B | -56.63%-2.45B | -35.18%769.27M | 12.50%-3.54B | 38.85%-2B | 96.54%-1.56B | 103.66%1.19B | 81.80%-4.04B |
| Minority profit | 13.46%-512.74M | -19.17%-905.29M | -50.03%-491.25M | -323.23%-2.21B | -249.84%-592.48M | -27.22%-759.66M | 5.70%-327.44M | 92.03%-522.84M | 109.18%395.42M | 78.50%-597.14M |
| Profit attributable to shareholders | 37.31%1.87B | 35.05%-1.8B | -22.07%-2.04B | 77.60%-232.56M | 72.06%1.36B | 19.38%-2.78B | 42.78%-1.67B | 97.31%-1.04B | 102.82%791.42M | 82.27%-3.45B |
| Basic earnings per share | 22.22%0.11 | 38.89%-0.11 | -9.09%-0.12 | 78.19%-0.0147 | 80.00%0.09 | 19.61%-0.18 | 42.11%-0.11 | 97.60%-0.0674 | 102.44%0.05 | 84.18%-0.2239 |
| Diluted earnings per share | 22.22%0.11 | 38.89%-0.11 | -9.09%-0.12 | 78.19%-0.0147 | 80.00%0.09 | 19.61%-0.18 | -0.11 | 97.60%-0.0674 | 0.05 | 84.18%-0.2239 |
| Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
| Accounting Standards | CAS (2007) | IAS | CAS (2007) | IAS | CAS (2007) | IAS | CAS (2007) | IAS | CAS (2007) | IAS |
| Audit Opinions | -- | -- | -- | Unqualified Opinion | -- | -- | -- | Unqualified Opinion | -- | -- |
| Auditor | -- | -- | -- | Deloitte Guan Huang Chen Fang Certified Public Accountants, Deloitte Huayong Certified Public Accountants (Special General Partnership) | -- | -- | -- | Deloitte Guan Huang Chen Fang Certified Public Accountants, Deloitte Huayong Certified Public Accountants (Special General Partnership) | -- | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.